EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
AHLL will become a 100% subsidiary of AHEL with 99.42% held by AHEL and balance in the ESOP pool
The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
Combination creates a leading, next generation claims operating system for payers, with end-to-end AI capabilities for claims, payments, care & utilization management, payment integrity, and member engagement, serving 115+ health plans
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
Subscribe To Our Newsletter & Stay Updated
